HAE241220P60000
- 0.91
- 0.000.00%
Haemonetics Newsroom
Haemonetics Analyst Ratings
Needham Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $112
Strategic Investment and Growth Potential Drive Buy Rating for Haemonetics
Raymond James Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $120
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $108 to $125
Haemonetics Is Maintained at Outperform by Barrington Research
Analysts' Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (AMN), DENTSPLY SIRONA (XRAY) and Haemonetics (HAE)
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $112 to $125
Haemonetics Analyst Ratings
Haemonetics Earns Buy Rating for Strong Q2 Performance and Margin Improvements
Haemonetics Is Maintained at Outperform by Barrington Research
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $108
Buy Rating Affirmed for Haemonetics With Promising Growth in Hospital Segment and Strong Plasma Market Position
Haemonetics Analyst Ratings
C.L. King Initiates Haemonetics(HAE.US) With Buy Rating, Announces Target Price $116
BofA Securities Initiates Haemonetics(HAE.US) With Hold Rating, Announces Target Price $85
Haemonetics Price Target Announced at $85.00/Share by B of A Securities
BTIG Initiates Haemonetics(HAE.US) With Buy Rating, Announces Target Price $112
Haemonetics Analyst Ratings
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $85